Literature DB >> 17786406

Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties.

Isabelle Rauly-Lestienne1, Elisa Boutet-Robinet, Marie-Christine Ailhaud, Adrian Newman-Tancredi, Didier Cussac.   

Abstract

5-HT(7) receptors are present in thalamus and limbic structures, and a possible role of these receptors in the pathology of schizophrenia has been evoked. In this study, we examined binding affinity and agonist/antagonist/inverse agonist properties at these receptors of a large series of antipsychotics, i.e., typical, atypical, and third generation compounds preferentially targeting D(2) and 5-HT(1A) sites. Adenylyl cyclase (AC) activity was measured in HEK293 cells stably expressing the human (h) 5-HT(7a) receptor isoform. 5-HT and 5-CT increased cyclic adenosine monophosphate level by about 20-fold whereas (+)-8-OH-DPAT, the antidyskinetic agent sarizotan, and the novel antipsychotic compound bifeprunox exhibited partial agonist properties at h5-HT(7a) receptors stimulating AC. Other compounds antagonized 5-HT-induced AC activity with pK (B) values which correlated with their pK (i) as determined by competition binding vs [(3)H]5-CT. The selective 5-HT(7) receptor ligand, SB269970, was the most potent antagonist. For antipsychotic compounds, the following rank order of antagonism potency (pK (B)) was ziprasidone > tiospirone > SSR181507 > or = clozapine > or = olanzapine > SLV-314 > SLV-313 > or = aripiprazole > or = chlorpromazine > nemonapride > haloperidol. Interestingly, pretreatment of HEK293-h5-HT(7a) cells with forskolin enhanced basal AC activity and revealed inverse agonist properties for both typical and atypical antipsychotics as well as for aripiprazole. In contrast, other novel antipsychotics exhibited diverse 5-HT(7a) properties; SLV-313 and SLV-314 behaved as quasi-neutral antagonists, SSR181507 acted as an inverse agonist, and bifeprunox as a partial agonist, as mentioned above. In conclusion, the differential properties of third generation antipsychotics at 5-HT(7) receptors may influence their antipsychotic profile.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786406     DOI: 10.1007/s00210-007-0182-6

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  69 in total

1.  The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects.

Authors:  Kurt A Krobert; Finn Olav Levy
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.

Authors:  Ronan Depoortere; Denis Boulay; Ghislaine Perrault; Olivier Bergis; Michel Decobert; Dominique Françon; Mireille Jung; Jacques Simiand; Philippe Soubrié; Bernard Scatton
Journal:  Neuropsychopharmacology       Date:  2003-11       Impact factor: 7.853

3.  Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor.

Authors:  Carol Smith; Tariq Rahman; Nicole Toohey; Joseph Mazurkiewicz; Katharine Herrick-Davis; Milt Teitler
Journal:  Mol Pharmacol       Date:  2006-07-26       Impact factor: 4.436

Review 4.  The 5-HT7 receptor: orphan found.

Authors:  R M Eglen; J R Jasper; D J Chang; G R Martin
Journal:  Trends Pharmacol Sci       Date:  1997-04       Impact factor: 14.819

5.  Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia.

Authors:  B Pouzet; M Didriksen; J Arnt
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

6.  Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.

Authors:  Liesbeth A Bruins Slot; Mark S Kleven; Adrian Newman-Tancredi
Journal:  Neuropharmacology       Date:  2005-07-11       Impact factor: 5.250

7.  Acute restraint stress increases 5-HT7 receptor mRNA expression in the rat hippocampus.

Authors:  J L Yau; J Noble; J R Seckl
Journal:  Neurosci Lett       Date:  2001-08-31       Impact factor: 3.046

8.  Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.

Authors:  Laurent Bardin; Mark S Kleven; Catherine Barret-Grévoz; Ronan Depoortère; Adrian Newman-Tancredi
Journal:  Neuropsychopharmacology       Date:  2005-10-19       Impact factor: 7.853

9.  Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression.

Authors:  M Guscott; L J Bristow; K Hadingham; T W Rosahl; M S Beer; J A Stanton; F Bromidge; A P Owens; I Huscroft; J Myers; N M Rupniak; S Patel; P J Whiting; P H Hutson; K C Fone; S M Biello; J J Kulagowski; G McAllister
Journal:  Neuropharmacology       Date:  2005-03       Impact factor: 5.250

10.  Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.

Authors:  Liesbeth A Bruins Slot; Luc De Vries; Adrian Newman-Tancredi; Didier Cussac
Journal:  Eur J Pharmacol       Date:  2006-02-21       Impact factor: 4.432

View more
  6 in total

Review 1.  5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.

Authors:  Stephanie W Watts; Robert Patrick Davis
Journal:  Cardiovasc Ther       Date:  2011-02       Impact factor: 3.023

2.  Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats.

Authors:  Masakuni Horiguchi; Mei Huang; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2011-03-25       Impact factor: 4.530

3.  5-HT is a potent relaxant in rat superior mesenteric veins.

Authors:  Stephanie W Watts; Emma S Darios; Bridget M Seitz; Janice M Thompson
Journal:  Pharmacol Res Perspect       Date:  2015-01-05

4.  Luciferase reporter gene assay on human 5-HT receptor: which response element should be chosen?

Authors:  Yiming Chen; Zhongyu Xu; Dang Wu; Jian Li; Cheng Song; Weiqiang Lu; Jin Huang
Journal:  Sci Rep       Date:  2015-01-27       Impact factor: 4.379

Review 5.  Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety.

Authors:  István Laszlovszky; Ágota Barabássy; György Németh
Journal:  Adv Ther       Date:  2021-06-06       Impact factor: 3.845

Review 6.  Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.

Authors:  Marco Solmi; Andrea Murru; Isabella Pacchiarotti; Juan Undurraga; Nicola Veronese; Michele Fornaro; Brendon Stubbs; Francesco Monaco; Eduard Vieta; Mary V Seeman; Christoph U Correll; André F Carvalho
Journal:  Ther Clin Risk Manag       Date:  2017-06-29       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.